Kuros Biosciences’ Post

CALCIO is a prospective, observational cohort study that is collecting real-world data on the use of intravascular lithotripsy (IVL) with the Shockwave Medical IVL system (Shockwave Medical, Inc.) to disrupt vascular calcifications in patients with chronic limb-threatening ischemia (CLTI). The study was initiated and is co-chaired by Dr. Raman uberoi, Prof. Peter Reimer and Prof. Christoph Binkert. CALCIO started patient enrolment on July 15, 2024, with the goal of recruiting 400 CLTI patients over the next two years. Learn more about CALCIO via CIRSE Insider! ➡️ https://t.ly/fkULP #CIRSEinsider #interventionalradiology Next Research

Exciting day in the lab! Patrick Denard, MD and Brian Werner, MD, spent the day in Thay Q Lee, PhD, MD, lab in Pasadena, CA, exploring methods to reduce the rate of acromial stress fractures in reverse shoulder arthroplasty. Results from this study could help advance surgical techniques for improving patient outcomes and the success rate of rTSA procedures. More to come on the findings of this study and its potential impact. #Innovation #Research #ShoulderArthroplasty #PatientOutcomes

The LeviCell® EOS system has officially been installed at Mayo Clinic's brand-new Integrated Education and Research Building (IERB) in Phoenix! This state-of-the-art addition to Mayo Clinic's shared resource lab will empower researchers across multiple labs and departments on campus with advanced cell enrichment and sample prep capabilities. 💡🔬 Our on-site seminar and hands-on training, presented by Jason McKinney and Cole Jones (he/him) were a resounding success, and included Principal Investigators, senior scientists, post-docs, and lab technicians, all eager to explore the power of Levitation Technology™. The training sessions were a fantastic opportunity to showcase how the EOS system is transforming workflows and driving innovation in research. 🙌 Here's to advancing science together at Mayo Clinic! 🥂✨ Don't get left behind - your research deserves the very best sample prep and cell enrichment. Visit https://bit.ly/3OGgY5l to learn more about the LeviCell EOS system. #LevitasBio #LeviCellEOS #MayoClinicResearch #LevitationTechnology #ScientificInnovation

Robeauté is developing a microrobot for novel therapies in hard-to-reach areas of the body. Designed specifically for the brain, at the service of neurosurgeons, the company’s microrobot will be able to freely navigate in other complex regions of the body to perform biopsies, collect precise anatomically localized data, and deliver therapies on-site, at the right dosage. Want to learn more about Robeauté? Catch Joana Cartocci’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is now open for LSI Europe ‘25 next September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

Read the key #InterventionalCardiology takeaways from 6 trials featured at #ACC2024 — drafted by SCAI experts! ➡️ https://ow.ly/uPYB50RgnPP

For more information about the CIRSE webinar "Get your clinical practice up to speed," visit our webpage: https://t.ly/dPu5X #IRgoingClinical #CIRSEwebinar #interventionalradiology

🌍 Innovation Spotlight: BiVacor – The Future of Artificial Hearts The third invention in our Greatest Inventions of 2024 series showcases a groundbreaking development in cardiac care. Nearly 25 years after losing his father to heart failure, Australian biomedical engineer Daniel Timms is transforming the future of medicine with his company, BiVacor. BiVacor has developed an artificial heart that mimics the function of a real human heart, propelling blood throughout the body. This year, as part of an ongoing feasibility study, three U.S. patients received BiVacor hearts. These artificial hearts kept the patients alive long enough to receive donor organs—a remarkable milestone in medical innovation. Daniel Timms’ ambitions don’t stop at short-term solutions. If early trials prove successful, BiVacor plans to test the device’s ability to function indefinitely, potentially eliminating the need for live-organ transplants. This groundbreaking innovation could redefine cardiac care, offering hope to countless patients and families worldwide. “This device didn’t exist for my family,” Timms says, “but it could be life-changing—and life-saving—for others.” What do you think about the potential of artificial hearts to replace live-organ transplants? Share your thoughts in the comments below, and stay tuned as we continue to spotlight the Greatest Inventions of 2024! Richard DiPilla Jeffrey Vahanian, CFP® Ligia Chacón Hernández Vinnie Curcio Jerin Hossain #Innovation #GreatestInventions #VattIPManagement #BiVacor #ArtificialHeart #MedicalBreakthroughs #TechnologyForGood #Biotechnology #BiomedicalEngineering

IVUS saves Lives! The 2024 ESC Guidelines rank IVUS at class 1, level A Join the courses to learn more. #IVUS #BostonScientific #leftMain #longLesions #trueBifurcations #BostonScientificCardiology

Perspectum and MRCP+ in the Spotlight! We’re thrilled to share that quantitative biliary metrics using MRCP+ are gaining significant attention in the medical community. As highlighted at The 2024 Liver Meeting, this breakthrough technology is proving to be a game-changer in understanding and managing primary sclerosing cholangitis (PSC). A special thank you to Sarah Finnegan, PhD, who presented new research findings from a partnership with the University of Toronto led by Dr Kartik Jhaveri and Dr Gideon Hirschfield showing that MRCP+ could detect changes in biliary tree anatomy over 10 years. PSC is a complex and challenging disease, but advancements like MRCP+ demonstrate how precision diagnostics can enable better clinical decisions, earlier interventions, and improved outcomes for patients worldwide. At Perspectum, we are committed to shaping a future where innovation meets impact, and this milestone brings us one step closer. 📖 Find the full article in the comments below! #Perspectum #MRCPPlus #PrecisionDiagnostics #PSC #HealthcareInnovation